targeting molecular subsets in metastatic colorectal
play

Targeting Molecular Subsets in Metastatic Colorectal Cancer (dMMR, - PowerPoint PPT Presentation

Jan 19, 2024 •202 likes •469 views

Targeting Molecular Subsets in Metastatic Colorectal Cancer (dMMR, HER2, or BRAF V600E): Is it Time for Frontline Targeted Therapy? Benjamin A. Weinberg, M.D. Assistant Professor of Medicine Lombardi Comprehensive Cancer Center Georgetown

  1. Targeting Molecular Subsets in Metastatic Colorectal Cancer (dMMR, HER2, or BRAF V600E): Is it Time for Frontline Targeted Therapy? Benjamin A. Weinberg, M.D. Assistant Professor of Medicine Lombardi Comprehensive Cancer Center Georgetown University

  2. The Colorectal Cancer Story Weinberg BA et al. Clin Adv Hematol Oncol 2016. de Gramont A et al. J Clin Oncol 2000. Hurwitz H et al. N Engl J Med 2004. Douillard JY et al. J Clin Oncol 2010. Souglakos J et al. Br J Cancer 2006. Van Cutsem E et al. J Clin Oncol 2011. Falcone A et al. J Clin Oncol 2007. Cremolini C et al. Lancet Oncol 2015.

  3. Right vs. Left Colon vs. Rectum Salem et al. Oncotarget 2017.

  4. IMMUNOTHERAPY FOR dMMR

  5. Response to Pembrolizumab Limited to MSI-H Tumors Le et al. N Engl J Med 2015.

  6. Best Reduction in Target Lesion: All Patients Presented By Michael Overman at 2018 Gastrointestinal Cancers Symposium

  7. Best Reduction in Target Lesions Presented By Thierry Andre at 2018 Gastrointestinal Cancers Symposium

  8. Progression-Free and Overall Survival Presented By Thierry Andre at 2018 Gastrointestinal Cancers Symposium

  9. Safety Summary Presented By Thierry Andre at 2018 Gastrointestinal Cancers Symposium

  10. Slide 27 Presented By Neil Segal at 2018 ASCO Annual Meeting

  11. HER2-DIRECTED THERAPY

  12. Sartore-Bianchi et al. Lancet Oncol 2016.

  13. ORR 30% Sartore-Bianchi et al. Lancet Oncol 2016. Siravegna et al. Clin Cancer Res 2019.

  14. MyPathway: Trastuzumab + Pertuzumab ORR 32% Meric-Bernstam et al. Lancet Oncol 2019.

  15. Meric-Bernstam et al. Lancet Oncol 2019.

  16. CETIRI MOUNTAINEER: Trastuzumab + Tucatinib Raghav et al. ASCO AM 2018. Strickler et al. ASCO AM 2017.

  17. BRAF-TARGETED THERAPY

  18. BRAF Mutations Carry a Poor Prognosis Cremolini et al. Lancet Oncol 2015.

  19. Introduction Presented By Scott Kopetz at 2017 ASCO Annual Meeting

  20. Study Design Presented By Scott Kopetz at 2017 ASCO Annual Meeting

  21. Primary Endpoint: Progression-free survival Presented By Scott Kopetz at 2017 ASCO Annual Meeting

  22. Secondary Endpoint: Overall Survival Presented By Scott Kopetz at 2017 ASCO Annual Meeting

  23. BEACON CRC Kopetz et al. ESMO GI 2019.

  24. BEACON CRC Kopetz et al. NEJM 2019.

  25. ORR 26% ORR 20% ORR 2% Kopetz et al. NEJM 2019.

  26. Questions? • baw12@gunet.georgetown.edu • @benweinbergmd

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

Hepatic Colorectal Metastasis: How Curable Metastatic Colorectal Cancer Much Progress Have We

Hepatic Colorectal Metastasis: How Curable Metastatic Colorectal Cancer Much Progress Have We

Hepatic Colorectal Metastasis: How Curable Metastatic Colorectal Cancer Much Progress Have We Made? Definition cure \ ky r\ n [ME, fr. OF, fr. ML &L; ML cura , fr. L, care ](14c) a complete or permanent solution or remedy

302 views • 12 slides
Management of MSS RAS wt Metastatic Colorectal Cancer: Sidedness and Anti EGFR

Management of MSS RAS wt Metastatic Colorectal Cancer: Sidedness and Anti EGFR

Management of MSS RAS wt Metastatic Colorectal Cancer: Sidedness and Anti EGFR Retreatment Benjamin A. Weinberg, M.D. Assistant Professor of Medicine Lombardi Comprehensive Cancer Center Georgetown University LEFT RIGHT Cancers for

500 views • 14 slides
Histopathology reporting of liver resection specimens for metastatic colorectal carcinoma:

Histopathology reporting of liver resection specimens for metastatic colorectal carcinoma:

Histopathology reporting of liver resection specimens for metastatic colorectal carcinoma: Current practice versus set standards Trainee: Shaniar Aziz Audit supervisor: Dina Tiniakos Background / Introduction Liver metastasis is the major

878 views • 34 slides
The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF

The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF

The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF V600E Tumor Mutations; HER2 and Other Potential Biomarkers Howard S Hochster, MD Distinguished Professor of Medicine Rutgers Robert Wood Johnson

238 views • 23 slides
How I Treat Metastatic Colorectal Cancer Making Sense of the Data Axel Grothey West Cancer

How I Treat Metastatic Colorectal Cancer Making Sense of the Data Axel Grothey West Cancer

How I Treat Metastatic Colorectal Cancer Making Sense of the Data Axel Grothey West Cancer Center, U Tennessee The Luxury of So Many Options . . . How Do We Personalize? Patient X Patient Y Patient Z PD-1 mAb What influences treatment

284 views • 27 slides
Challenges in Colorectal Cancer Wendy L Frankel, MD Chair of Pathology Director of GI/Liver

Challenges in Colorectal Cancer Wendy L Frankel, MD Chair of Pathology Director of GI/Liver

5/28/2016 Outline- Colorectal Cancer Tumor T staging and serosal involvement Neoadjuvant treatment and staging Lymph node N staging and tumor deposits Molecular and ancillary studies Challenges in Colorectal Cancer Wendy L

402 views • 16 slides
Molecular/genetic stratification for first line treatment of recurrent or metastatic endometrial

Molecular/genetic stratification for first line treatment of recurrent or metastatic endometrial

Molecular/genetic stratification for first line treatment of recurrent or metastatic endometrial cancer: Are we ready? Karen Lu, MD MD Anderson/G-GOC GCIG Endometrial cancer session June 1, 2017 It always seems impossible until its

669 views • 29 slides
Molecular classification of colorectal cancer Fred T Bosman University Institute of Pathology

Molecular classification of colorectal cancer Fred T Bosman University Institute of Pathology

Molecular classification of colorectal cancer Fred T Bosman University Institute of Pathology Lausanne Current WHO classification of carcinoma of the colorectum Adenocarcinoma, NOS Cribriform comedo-type adenocarcinoma Medullary

633 views • 47 slides
Molecular Characterization and Therapeutic Targeting of TFE Fusion Kidney Cancers Srinivas R.

Molecular Characterization and Therapeutic Targeting of TFE Fusion Kidney Cancers Srinivas R.

9/30/2020 Molecular Characterization and Therapeutic Targeting of TFE Fusion Kidney Cancers Srinivas R. Viswanathan, MD, PhD Dana-Farber Cancer Institute 10-22-2020 1 Translocation renal cell carcinoma (tRCC) Overview Aggressive type of

106 views • 8 slides
Diffuse Large B-cell Lymphomas Targeting Molecular Pathways Wyndham H. Wilson, M.D., Ph.D.

Diffuse Large B-cell Lymphomas Targeting Molecular Pathways Wyndham H. Wilson, M.D., Ph.D.

Diffuse Large B-cell Lymphomas Targeting Molecular Pathways Wyndham H. Wilson, M.D., Ph.D. Evolution of DLBCL therapeutics. Kieron Dunleavy et al. Clin Cancer Res 2014;20:5182-5193 DLBCL outcomes following R-CHOP by Cell of Origin Method Hans

969 views • 48 slides
Molecular Therapeutics of Cancer Research Meeting Targeting the Menin-MLL1 Interaction Site as a

Molecular Therapeutics of Cancer Research Meeting Targeting the Menin-MLL1 Interaction Site as a

Molecular Therapeutics of Cancer Research Meeting Targeting the Menin-MLL1 Interaction Site as a Treatment for Mixed Lineage Leukemia-rearranged (MLL-r) and NPM1c+ AML Jerry McGeehan Syndax Pharmaceuticals 1 Outline Overview of Mixed

761 views • 27 slides
Scope of the Problem Liver Disease Should be Resected First (with the primary tumor)

Scope of the Problem Liver Disease Should be Resected First (with the primary tumor)

Synchronous Hepatic Colorectal Metastases: Scope of the Problem Liver Disease Should be Resected First (with the primary tumor) Colorectal cancer in USA New cases 150,000 Metastatic liver disease 75,000 20,000 * Synchronous

279 views • 7 slides
targeting innate and adaptive immunity in a phase I/II study of intratumoral IMO-2125 in

targeting innate and adaptive immunity in a phase I/II study of intratumoral IMO-2125 in

Reactivating the anti-tumor immune response by targeting innate and adaptive immunity in a phase I/II study of intratumoral IMO-2125 in combination with systemic ipilimumab in patients with anti-PD-1 refractory metastatic melanoma Cara

729 views • 21 slides
Lattimer subsets of Art IE ) field function for Fixed & sub extensions of E subsets et Aut

Lattimer subsets of Art IE ) field function for Fixed & sub extensions of E subsets et Aut

of Characters Independence fields Fixed of I : subgroups Lattimer subsets of Art IE ) field function for Fixed & sub extensions of E subsets et Aut ( E ) lie , inclusion reversing ) " contravariant " not too small ) (

436 views • 12 slides
Which is the best test for colorectal cancer screening? Giovanna da Silva, MD, FACS, FASCRS

Which is the best test for colorectal cancer screening? Giovanna da Silva, MD, FACS, FASCRS

Which is the best test for colorectal cancer screening? Giovanna da Silva, MD, FACS, FASCRS Staff, Department of Colorectal Surgery Director of Clinical Research Cleveland Clinic Florida Disclosures None Colorectal Cancer (CRC) Siegeel.

469 views • 27 slides
5/22/19 Colorectal Cancer An Evidence Based Approach to Colorectal Lifetime incidence of 6%

5/22/19 Colorectal Cancer An Evidence Based Approach to Colorectal Lifetime incidence of 6%

5/22/19 Colorectal Cancer An Evidence Based Approach to Colorectal Lifetime incidence of 6% Cancer Screening Prevalence of 1% in asymptomatic patients aged 50-75 Common cause of cancer death, 2nd in men, 3rd in women Jay Ryan,

752 views • 10 slides
Contraceptive Coverage: What does it include? ACA requires coverage of the full range of FDA-

Contraceptive Coverage: What does it include? ACA requires coverage of the full range of FDA-

4/13/2015 Coverage of Contraceptive Services: A Review of Health Insurance Plans in Five States Laurie Sobel, J.D. Senior Policy Analyst, Womens Health Policy Kaiser Family Foundation Washington, DC April 16, 2015 Contraceptive Coverage:

513 views • 11 slides
Stochastic modeling and algorithms for structured data and distributed systems Long Nguyen

Stochastic modeling and algorithms for structured data and distributed systems Long Nguyen

Stochastic modeling and algorithms for structured data and distributed systems Long Nguyen Department of Statistics Department of Electrical Engineering and Computer Science University of Michigan 1 Structured data Data that are rich in

431 views • 13 slides
Healthy Start Our goal is to reduce Colorados current premature birth rate from 8.7% to

Healthy Start Our goal is to reduce Colorados current premature birth rate from 8.7% to

5/2/2017 Welcome to the NICU Consortium April 26, 2017 Agenda Building Partnerships 9:00 am Welcome, Announcements 9:15 am Primitive Reflexes: Implications for infants and children home from the NICU Jennifer Spiric, PT, DPT 2016-2017

926 views • 12 slides
84.314 84.314 Analytical Chemistry II Analytical Chemistry II (Instrumental Analysis)

84.314 84.314 Analytical Chemistry II Analytical Chemistry II (Instrumental Analysis)

84.314 84.314 Analytical Chemistry II Analytical Chemistry II (Instrumental Analysis) (Instrumental Analysis) Dr. David K. Ryan Dr. David K. Ryan Department of Chemistry Department of Chemistry University of Massachusetts Low ell

526 views • 29 slides
Personalized Medicine and Artificial Intelligence Michael R. Kosorok, Ph.D. Department of

Personalized Medicine and Artificial Intelligence Michael R. Kosorok, Ph.D. Department of

Outline Personalized Medicine and Artificial Intelligence Michael R. Kosorok, Ph.D. Department of Biostatistics University of North Carolina at Chapel Hill Summer, 2012 1/ 50 Outline Outline 1 Overview of Personalized Medicine Introduction

819 views • 50 slides
Up-to-date survival estimates from prognostic models using temporal recalibration Sarah Booth 1

Up-to-date survival estimates from prognostic models using temporal recalibration Sarah Booth 1

Up-to-date survival estimates from prognostic models using temporal recalibration Sarah Booth 1 Mark J. Rutherford 1 Paul C. Lambert 1 , 2 1 Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK 2

1.02k views • 56 slides
1 This session serves as a follow-up to the p previous presentation on the diagnosis and

1 This session serves as a follow-up to the p previous presentation on the diagnosis and

1 This session serves as a follow-up to the p previous presentation on the diagnosis and prognosis of ASR-affected transportation structures. This presentation will describe past and ongoing field trials that have attempted to reduce future

856 views • 53 slides
Classifica4on Binary classifica,on Given a set of examples ( x i , y i ) , where y i = + 1,

Classifica4on Binary classifica,on Given a set of examples ( x i , y i ) , where y i = + 1,

4/17/09 CSCI1950Z Computa4onal Methods for Biology Lecture 18 Ben Raphael April 8, 2009 hIp://cs.brown.edu/courses/csci1950z/ Classifica4on Binary classifica,on Given a set of examples ( x i , y i ) , where y i = + 1, from unknown

266 views • 12 slides

More recommend